It is a world-first that pure semaglutide processed with DehydraTECH technology without SNAC will be compared directly to SNAC-enabled Rybelsus® in a multiple week human study.

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

followed by 14mg oral semaglutide once daily (OD) formulate with absorption enhancer sodium-N-(8-(2-hydroxybenzoyl) amino caprylate (SNAC) or 14mg placebo OD with SNAC, then at the ending of week ...

caprylate (SNAC), which has been used to enhance the absorption of GLP-1 peptides, such as semaglutide. Utilization of SNAC to protect infliximab from enzymatic degradation or permeation ...

Semaglutide is a GLP-1 receptor agonist that ... clinical trials that tested a variety of medicines. Novo acquired the SNAC ...